Loading...
•
Jun 30, 2022
Capricor Q2 2022 Earnings Report
Capricor Therapeutics reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Key Takeaways
Capricor Therapeutics reported a net loss of $7.1 million, or $0.29 per share, for the second quarter of 2022. As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $51.4 million.
First patient treated in HOPE-3, the pivotal Phase 3 clinical trial of CAP-1002 in Duchenne Muscular Dystrophy.
Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Non-Ambulant Duchenne Muscular Dystrophy Patients Presented at PPMD’s 2022 Annual Conference.
Requesting Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy.
Pipeline Expansion Underway Using Engineered Exosomes
Forward Guidance
Capricor believes that its available cash and cash equivalents will be sufficient to cover anticipated expenses and capital requirements into the second quarter of 2024.
Positive Outlook
- Requesting meeting with FDA to discuss next steps in our CAP-1002 DMD program
- Publication of additional preclinical work related to our engineered exosomes platform
- Full enrollment of HOPE-3 expected by the third quarter of 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...